A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Liping Dou, Sai Huang, Yu Jing, Ning Le, Meng Li, Daihong Liu, Qingyang Liu, Lingmin Xu, Jingjing Yang, Xiawei Zhang, Weijia Zhao

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: Netherlands : International immunopharmacology , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 560574

Thêm vào giỏ Liên kết toàn văn

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by elevated mortality. Epigenetic therapy plays an essential role in the treatment of AML. However, the clinical outcomes of the combination of multiple epigenetic agents and conventional chemotherapy remain unclear. We conducted a phase 2 study to evaluate the clinical safety and efficacy of chidamide combined with CAG and venetoclax-azacitidine (referred to as CACAG-VEN) in AML patients (NCT05659992). Patients received induction treatment with aclarubicin (10 mg/m

Tạo bộ sưu tập với mã QR